NCT03502876View on ClinicalTrials.gov

Tolerance and Resistance to Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL

CompletedOBSERVATIONAL
Enrollment

198

Participants

Timeline

Start Date

November 2, 2017

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2019

Conditions
B Cell Chronic Lymphocytic Leukemia
Trial Locations (2)

37044

FILO French Innovative Leukemia Organization, Tours

Project manager, Tours

All Listed Sponsors
lead

French Innovative Leukemia Organisation

OTHER

NCT03502876 - Tolerance and Resistance to Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL | Biotech Hunter | Biotech Hunter